98%
921
2 minutes
20
Pulmonary hypertension (PH) in chronic obstructive pulmonary disease (COPD) is associated with worse clinical outcomes and decreased survival rates. In absence of disease specific diagnostic/therapeutic targets and unclear pathophysiology, there is an urgent need for the identification of potential genetic/molecular markers and disease associated pathways. The present study aims to use a bioinformatics approach to identify and validate hypoxia-associated gene signatures in COPD-PH patients. Additionally, hypoxia-related inflammatory profile is also explored in these patients. Microarray dataset obtained from the Gene Expression Omnibus repository was used to identify differentially expressed genes (DEGs) in a hypoxic PH mice model. The top three hub genes identified were further validated in COPD-PH patients, with chemokine (C-X-C motif) ligand 9 (CXCL9) and CXCL12 showing significant changes in comparison to healthy controls. Furthermore, multiplexed analysis of 10 inflammatory cytokines, tumor necrosis factor alpha (TNF-α), transforming growth factor β (TGF-β), interleukin 1-beta (IL-1β), IL-4, IL-5, IL-6, IL-13, IL-17, IL-18 and IL-21 was also performed. These markers showed significant changes in COPD-PH patients as compared to controls. They also exhibited the ability to differentially diagnose COPD-PH patients in comparison to COPD. Additionally, IL-6 and IL-17 showed significant positive correlation with systolic pulmonary artery pressure (sPAP). This study is the first report to assess the levels of CXCL9 and CXCL12 in COPD-PH patients and also explores their link with the inflammatory profile of these patients. Our findings could be extended to better understand the underlying disease mechanism and possibly used for tailoring therapies exclusive for the disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.rmed.2024.107658 | DOI Listing |
J Vis Exp
July 2025
Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine;
Pulmonary hypertension (PH) is the most prevalent cardiovascular complication of chronic obstructive pulmonary disease (COPD). Dyspnea is the most prevalent and distressing symptom in Pulmonary Hypertension Associated with COPD (PH-COPD) patients. This study elucidates the operational details of electroacupuncture therapy, encompassing instrument preparation, acupuncture point selection, procedure, precautions, and emergency handling.
View Article and Find Full Text PDFJ Ethnopharmacol
July 2025
Traditional Chinese Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China. Electronic address:
Ethnopharmacological Relevance: COPD-PH is a common and severe complication of COPD, posing significant challenges to patient survival and quality of life due to its poor prognosis. However, current treatment options remain clinically unsatisfactory. Tianlong kechuanling (TL), a traditional Chinese medicine compound hospital preparation, has been clinically employed for treating cor pulmonale, although its underlying mechanisms remain elusive.
View Article and Find Full Text PDFPathol Res Pract
September 2025
Department of Medical Oncology, The Quzhou Afiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou 324000, PR China; Core Facility, The Quzhou Afiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou 324000, PR China. Electronic address: zhengquan
Aims: This study aims to comprehensively assess the effectiveness and safety of combining sildenafil with statins for managing pulmonary hypertension secondary to COPD. By conducting a comprehensive meta-analysis, we seek to provide robust evidence to inform and optimize clinical decision-making for this challenging condition.
Methods: A systematic search of the literature was performed across various databases, such as CNKI, VIP Data, Wanfang Data, PubMed, Web of Science, and the Cochrane Library, to identify RCTs that assess the effectiveness of sildenafil and statins in combination for treating PH secondary to COPD.
ERJ Open Res
July 2025
Department of Medicine V, University Hospital, LMU Munich, Comprehensive Pneumology Center (CPC), Member of the German Center for Lung Research (DZL), Munich, Germany.
Background: Pulmonary hypertension (PH) associated with COPD contributes to morbidity and mortality. Further characterisation to improve management is warranted. The aim of the study was to apply the recently proposed PH classification and to assess the association of lung volume involvement and PH over the course of disease in patients with advanced COPD.
View Article and Find Full Text PDFEur Respir J
August 2025
Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
https://bit.ly/4jEy5RT
View Article and Find Full Text PDF